GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.
Biomed Pharmacother
; 142: 112011, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1340557
ABSTRACT
Since the start of the outbreak of coronavirus disease 2019 in Wuhan, China, there have been more than 150 million confirmed cases of the disease reported to the World Health Organization. The beta variant (B.1.351 lineage), the mutation lineages of SARS-CoV-2, had increase transmissibility and resistance to neutralizing antibodies due to multiple mutations in the spike protein. N501Y, K417N and E484K, in the receptor binding domain (RBD) region may induce a conformational change of the spike protein and subsequently increase the infectivity of the beta variant. The L452R mutation in the epsilon variant (the B.1.427/B.1.429 variants) also reduced neutralizing activity of monoclonal antibodies. In this study, we discovered that 300 µg/mL GB-2, from Tian Shang Sheng Mu of Chiayi Puzi Peitian Temple, can inhibit the binding between ACE2 and wild-type (Wuhan type) RBD spike protein. GB-2 can inhibit the binding between ACE2 and RBD with K417N-E484K-N501Y mutation in a dose-dependent manner. GB-2 inhibited the binding between ACE2 and the RBD with a single mutation (K417N or N501Y or L452R) except the E484K mutation. In the compositions of GB-2, glycyrrhiza uralensis Fisch. ex DC., theaflavin and (+)-catechin cannot inhibit the binding between ACE2 and wild-type RBD spike protein. Theaflavin 3-gallate can inhibit the binding between ACE2 and wild-type RBD spike protein. Our results suggest that GB-2 could be a potential candidate for the prophylaxis of some SARS-CoV-2 variants infection in the further clinical study because of its inhibition of binding between ACE2 and RBD with K417N-E484K-N501Y mutations or L452R mutation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Catechin
/
Biflavonoids
/
Spike Glycoprotein, Coronavirus
/
Gallic Acid
/
Angiotensin-Converting Enzyme 2
/
SARS-CoV-2
/
COVID-19
Type of study:
Prognostic study
Topics:
Traditional medicine
/
Variants
Limits:
Humans
Language:
English
Journal:
Biomed Pharmacother
Year:
2021
Document Type:
Article
Affiliation country:
J.biopha.2021.112011
Similar
MEDLINE
...
LILACS
LIS